![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
在对外围T细胞淋巴瘤的最前沿治疗方面,最近的进展和未来的前景
Yuko Shirouchi1, Nobuhiko Yamauchi1, Dai Maruyama1
1Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo, Japan.
Japanese journal of clinical oncology
|October 9, 2025
概括
周围T细胞淋巴瘤 (PTCL) 治疗正在发展. BV-CHP显示CD30阳性PTCL的生存率有所改善,而CHOP仍然是CD30阴性类型的标准,未来的战略重点是个性化医学.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 周围T细胞淋巴瘤 (PTCL) 是一组多样化的具有不良预后的侵袭性淋巴瘤.
- 最近的进展已经改进了PTCL分类,特别是分组毛囊辅助T细胞 (TFH) 淋巴瘤.
- 像CHOP这样的既定治疗方法都有局限性,这推动了寻找更有效的疗法.
研究的目的:
- 审查当前的治疗标准和近期在周围T细胞淋巴瘤 (PTCL) 的进展.
- 突出ECHELON-2试验对CD30阳性PTCL管理的影响.
- 讨论PTCL治疗的不断变化的格局,包括新型药物和未来的方向.
主要方法:
- 关于PTCL治疗的当前文献和临床试验数据的综述.
- 对ECHELON-2试验结果的分析,比较BV-CHP和CHOP疗法.
- 讨论TFH起源淋巴瘤的世卫组织分类更新.
主要成果:
- 埃希伦-2试验确定BV-CHP在CD30阳性PTCL中优于CHOP,改善了生存率.
- 由于新药组合的毒性问题,CHOP仍然是CD30阴性PTCL的标准.
- 在PTCL中前期自身干细胞移植的作用正在调查中.
结论:
- 对于CD30阳性PTCL来说,BV-CHP是一个显著的进步.
- 对CD30阴性PTCL的治疗主要依赖于CHOP,等待进一步的研究.
- 未来的PTCL治疗可能将涉及基于分子/遗传特征和生物标志物的分层方法.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K